Clinical trials: Neoadjuvant Radiotherapy
Rectal Cancer
Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer
The purpose of this study is to evaluate the use of chemotherapy, radiation therapy and bevacizumab before surgery in patients with locally advanced rectal cancer (LARC).
- Trial name
- BRANCH (NCT01481545)
- Testing
- Radiation therapy, Oxaliplatin, Raltitrexed
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute, Naples
Esophageal Cancer Stage III
The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC
Background The promising therapeutic outcomes of neoadjuvant chemoimmnotherapy in the treatment of locally advanced esophageal squamous cell carcinoma (ESCC) have been confirmed by several phase II clinical trials and have been…
- Trial name
- NCT06965829
- Testing
- Tislelizumab, Carboplatin and Paclitaxel and Radiation Therapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Chest Hospital
Neoadjuvant Radiotherapy, Breast Cancer
Neoadjuvant Radiotherapy for Breast Cancer
The goal of this clinical trial is to compare the effects of neoadjuvant radiotherapy and adjuvant radiotherapy in patients with breast cancer.
- Trial name
- NCT06313073
- Testing
- Neoadjuvant radiotherapy, adjuvant radiotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Changhai Hospital
Rectal Cancer, Metastatic
Short Course Radiotherapy, Unresectable Rectal Cancer, Liver Metastasis
The purpose of this study is the increase of resection rate of primary cancer in rectal after short course radiotherapy without interrupt chemotherapy schedule during the period of chemotherapy.
- Trial name
- NCT03022734
- Testing
- chemotherapy, radiotherapy
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Yonsei University
Rectal Neoplasm Malignant
Total Mesorectal Excision(TME) With Lateral Lymph Node Dissection Versus TME After Neoadjuvant Chemo-radiotherapy
Treatment for Low rectal cancer, especially in patients with regional lymph node metastasis are quite different between Japanese guideline (JSCCR) and western countries' guideline (NCCN, ESMO).
- Trial name
- TELEPHOME (NCT03587480)
- Testing
- TME+LLND, TME+nCRT
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
HNSCC, PD-1
PD-1 Inhibitor Therapy Versus Radiotherapy in MPR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-006)
Head and neck malignant tumors rank as the sixth most common type of malignancy worldwide, with approximately 90% being squamous cell carcinoma (Head and Neck Squamous Cell Carcinoma, HNSCC).
- Conditions
- HNSCC, PD-1, Radiotherapy
- Trial name
- NCT07090707
- Testing
- PD-1inhibitor, radiotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Glioblastoma
Neoadjuvant Temozolomide Combined With Simultaneous IMRT for Treatment of Glioblastoma
This study is a prospective, multi-center, randomized controlled clinical study. Indications: Glioblastoma diagnosed after surgery (WHO grade IV).
- Trial name
- NCT04829097
- Testing
- Temozolomide
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Rectal Cancer, Rectal Cancer Patients
Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial
Neoadjuvant fluoropyrimidine-based chemoradiotherapy followed by total mesorectal excision (TME) is the standard of care for locally advanced rectal cancer (LARC); however, pathologic complete response (pCR) rates are low.
- Trial name
- NCT06850090
- Testing
- TAS-102, Capecitabine
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Shandong Cancer Hospital and Institute
Rectal Neoplasms
CONVERT: Neoadjuvant Chemotherapy Alone Versus Preoperative Chemoradiation for Locally Advanced Rectal Cancer Patients
Although neoadjuvant radiotherapy greatly decreases local recurrence in locally advanced rectal cancer patients undergoing surgery, it inevitably results in short-term and long-term toxicities.
- Trial name
- NCT02288195
- Testing
- Oxaliplatin, capecitabine, Radiation
- Where
- China
- Volunteers
- 663 people
- Sponsor
- Sun Yat-sen University
Rectal Cancer, Adenocarcinoma
SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC
This is a single-center, exploratory clinical study for patients with newly diagnosed, high-risk, locally advanced rectal cancer.
- Trial name
- NCT07474103
- Testing
- SCRT, Liposomal Irinotecan, Oxaliplatin
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Rectal Cancer
Preoperative Panitumumab and Radiotherapy in Rectal Cancer
The purpose of this study is to investigate the activity of panitumumab in combination with standard preoperative radiotherapy in locally advanced rectal cancer, followed by complete surgery and adjuvant chemotherapy.
- Trial name
- PrePaRad (NCT00973193)
- Testing
- panitumumab
- Where
- 8 sites in Belgium
- Volunteers
- 20 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Chemotherapy, Radiation Therapy
Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma
The investigators conducted a phase II, prospective, two-arm clinical study to explore the efficacy of Camrelizumab combined with chemotherapy versus chemoradiotherapy for conversion therapy of potentially resectable advanced…
- Trial name
- NCT05821452
- Testing
- Camrelizumab, Paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fujian Medical University Union Hospital
Pancreatic Neoplasms
Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Patients With Borderline Resectable Pancreatic Cancer
The goal of the present study is to test if in situations of borderline resectable patients a neoadjuvant treatment combining Gemzar-Abraxane and stereotactic radiosurgery could increase the median OS rates above 30 months that…
- Trial name
- CKPancreas (NCT03199144)
- Testing
- Chemotherapy, Stereotactic radiotherapy, Surgery
- Where
- Luxembourg
- Sponsor
- Centre Francois Baclesse, Luxembourg
Rectal Cancer
Neoadjuvant Chemoradiation With 5-FU(or Capecitabine) and Oxaliplatin Combined With Hyperthermia in Rectal Cancer
This trial examines the feasibility, effectiveness and safety of a combination of radiotherapy (over a period of five weeks) and chemotherapy (with 5-FU or Capecitabine and Oxaliplatin) and 10 fractions of deep regional…
- Trial name
- HyRec (NCT01716949)
- Testing
- Radiotherapy, Hyperthermia, 5-Fluorouracil
- Where
- 6 sites in Germany
- Volunteers
- 59 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Squamous Cell Carcinoma of the Head and Neck
ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma
There are currently no useful tests to identify patients who will respond to cetuximab therapy, notably because EGFR levels do not correlate with the clinical responses observed.
- Trial name
- NCT01218048
- Testing
- Cetuximab, Surgery, Post-surgical radiation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Robert Ferris
Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer
2-Drug Combination Chemotherapy Followed by Radiotherapy. Paclitaxel, TAX, NSC-125973; Cisplatin, CDDP, NSC-119875; followed by chest irradiation using 4-15 MV photons.
- Trial name
- NCT00001499
- Testing
- paclitaxel, cisplatin, chest radiotherapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy
This study proposes to evaluate the safety and efficacy of an anti-PD-L1 (durvalumab) agent as neoadjuvant therapy in patients diagnosed with localized NSCLC who are planned to undergo radical RT or CRT.
- Trial name
- IDEAR (NCT05267392)
- Testing
- Durvalumab, standard of care RT/RCT
- Where
- Portugal
- Volunteers
- 30 people
- Sponsor
- Instituto Portugues de Oncologia, Francisco Gentil, Porto
Rectal Cancer
Neoadjuvant FOLFOX6 Chemotherapy With or Without Radiation in Rectal Cancer
RATIONALE: Preoperative 5-Fu based chemoradiation has become standard treatment for stage 2/3 rectal cancer. However whether these patients, especially T3N0-1M0 patients, really need radiation for local control after total…
- Trial name
- FOWARC (NCT01211210)
- Testing
- fluorouracil, fluorouracil, oxaliplatin
- Where
- China
- Volunteers
- 495 people
- Sponsor
- Sun Yat-sen University
Gastric Cancer, Adenocarcinoma
Induction Chemotherapy, Chemoradiotherapy and Surgery in Locally Advanced Gastric Cancer Patients
The aim of this study is to evaluate the efficacy of a neoadjuvant approach in patients with locally advanced gastric cancer and the identification of prognostic factors.
- Conditions
- Gastric Cancer, Adenocarcinoma, Effects of Chemotherapy, Surgery
- Trial name
- NCT02454647
- Testing
- Induction chemotherapy, Radiotherapy with concurrent chemotherapy, Salvage surgery
- Where
- Spain
- Volunteers
- 46 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Rectal Cancer
Short-course Radiation (SCRT) Followed by 6 Cycles of Cadonilimab Plus MFOLFOX6 As Neoadjuvant Therapy for Patients with Locally Advanced Rectal Cancer (LARC): a Multicenter, Two-arm Parallel, Open-label, Randomised Phase III Trial (NeoCaCRT-III)
The goal of this clinical trial is to learn if neoadjuvant short-course radiation (SCRT) followed by 6 cycles of cadonilimab plus mFOLFOX6 works to treat patients with locally advanced rectal cancer (LARC).
- Trial name
- NeoCaCRT-III (NCT06832917)
- Testing
- AK104 plus, Chemo only
- Volunteers
- 238 people
- Sponsor
- Wan He